FABOMOTIZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC2=C(NC(SCCN3CCOCC3)=N2)C=C1

InChI

InChIKey=WWNUCVSRRUDYPP-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf
Curator's Comment: description was created based on several sources, including http://pro-pharma.biz/?page_id=171

Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Agonist 2678		5.9 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Generalized anxiety disorder 32 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Neurasthenia 5 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Adjustment disorder 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Insomnia 108 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Withdrawal syndrome 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Palliative	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006

PubMed

Title	Date	PubMed
[State of hemopoiesis under exposure to low doses of ionizing radiation and emotional stress during treatment with anxiolytic aphobazole].	2001 Jan-Feb	11253700
[Clinical study of the selective anxiolytic agent afobazol].	2001 Mar-Apr	11548440
[Pharmacological regulation of emotional stress reactions].	2003	14724970
Effect of noopept and afobazole on the development of neurosis of learned helplessness in rats.	2003 Aug	14631499
[Comparative electroencephalographic evaluation of anxiolytics afobazol and diazepam in MR and MNRA inbred rats with different anxiety levels].	2003 Mar-Apr	12962046
[Afobazole increases cerebral blood flow in rats with global brain ischemia].	2004 Sep-Oct	15559627
Neuroprotective properties of afobazol in vitro.	2005 Aug	16282999
[Effect of afobazole on transmembrane ion currents in mollusk neurons].	2005 Sep-Oct	16277200
[Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia].	2006 Jul-Aug	16995439
[Evidence for the neuroprotective properties of afobazole in experimental model of focal brain ischemia].	2006 Jul-Aug	16995428
[Effect of afobazole on brain-ischemia-induced anxiety in rats].	2006 Mar-Apr	16845930
[A comparative study of the effect of afobazole on brain monoamine systems in BALB/C and C57BL/6 mice].	2006 Sep-Oct	17153957
[Pharmacokinetics of afobazole in rats].	2007 Mar-Apr	17523455
Tissue availability of afobazole and its major metabolites in rats.	2007 May	18239776
In vivo effects of afobazole (2-mercaptobenzimidazole derivative) on the 7,12-dimethylbenz [alpha]anthracene-induced oncogene and suppressor gene expression.	2007 Nov-Dec	18210756
Effect of afobazole on teratogenic activity of cyclophosphamide in rats.	2008 Apr	19110587
[Antimutagenic and antiteratogenic properties of afobazole].	2009 Jan-Feb	19334511
[Specific effects of selective anxiolytic afobazole on the cardiovascular system].	2009 Jan-Feb	19334510
[Afobazole effect on heart rate variability in rats with different behaviors in the "open field" test].	2009 Jan-Feb	19334509
[Neuroprotective effects of afobazole in a hemorrhagic stroke model].	2009 Jan-Feb	19334507
[Afobazole influence on antinociceptive properties of morphine].	2009 Jan-Feb	19334506
[Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons].	2009 Jan-Feb	19334503
[Neuroreceptor mechanisms of the afobazole effect].	2009 Jan-Feb	19334502
Effect of afobazole on DNA damage in patients with systemic lupus erythematosus.	2009 Oct	20396750
Neuroprotective properties of afobazole in repeated hemorrhagic stroke modeling in aged rats.	2010 Aug	21113492
[Model study of afobazole distribution in pregnant and lactating female rats and infant rat pups].	2010 Aug	20919552
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].	2010 Mar	20408420
[Antiarrhythmic properties of afobazole and other 2-mercaptobensimidazole derivatives].	2010 May	20597362
[Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation].	2010 May	20597361
[Comparative study of the interoceptive effects of afobazole and diazepam].	2010 Oct	21254504
Comparative analysis of tissue availability for afobazole and compound M-11.	2010 Sep	21246091
On the mechanism of antifibrillatory effect of afobazole.	2010 Sep	21246090
Effect of afobazole on genotoxic effects of tobacco smoke in the placenta and embryonic tissues of rats.	2010 Sep	21246089

Patents

Sample Use Guides

In Vivo Use Guide

For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Experiments on immortalized hippocampal cell culture of mice showed that afobazole increases the NGF level in a final concentration of 10(-8) M and the BDNF level in final concentrations from 10(-8) to 10(-5) M.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:50:01 GMT 2023` Edited by `admin` on `Sat Dec 16 17:50:01 GMT 2023`
Record UNII	0F8K1X115C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FABOMOTIZOLE

Official Name

English

AFOBAZOLE

Common Name

English

1H-BENZIMIDAZOLE, 5-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-

Systematic Name

English

APHOBAZOLE

Common Name

English

AFOBAZOL

Common Name

English

OBENOXAZINE

Common Name

English

Fabomotizole [WHO-DD]

Common Name

English

fabomotizole [INN]

Common Name

English

5-ETHOXY-2-((2-(MORPHOLIN-4-YL)ETHYL)SULFANYL)-1H-BENZIMIDAZOLE

Systematic Name

English

CM-346

Code

English

Classification Tree Code System Code

WHO-ATC

N05BX04